Bankers and underwriters have plenty to be thankful for. Bond issuance is running hot, this year’s IPO count is up (at least ...

Shortly after Alkermes and Avadel announced their deal, Lundbeck made an unsolicited offer of $23 per share, including $21 ...

Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.

Investing.com -- Pfizer Inc plans to expand its obesity portfolio globally with a focus on oral medications following its Metsera acquisition, Chief Financial Officer Dave Denton said at the Jefferies ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...

Pfizer (PFE) stock is in focus as the company plans a $5B bond offering to fund its acquisition of obesity drug developer Metsera and other purposes. Read more here.

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive ...

Under the agreement, Kretinsky’s EPH will receive TotalEnergies stock equal to that amount, the French energy giant said in a ...

Just one month into his job, Novo Nordisk’s new chief executive went to bed one night in September thinking he had secured a ...